全文获取类型
收费全文 | 1370篇 |
免费 | 54篇 |
国内免费 | 81篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 69篇 |
妇产科学 | 14篇 |
基础医学 | 155篇 |
口腔科学 | 24篇 |
临床医学 | 227篇 |
内科学 | 352篇 |
皮肤病学 | 33篇 |
神经病学 | 29篇 |
特种医学 | 302篇 |
外科学 | 81篇 |
综合类 | 27篇 |
预防医学 | 30篇 |
眼科学 | 16篇 |
药学 | 77篇 |
肿瘤学 | 65篇 |
出版年
2022年 | 5篇 |
2021年 | 8篇 |
2019年 | 12篇 |
2018年 | 7篇 |
2017年 | 9篇 |
2016年 | 11篇 |
2015年 | 19篇 |
2014年 | 11篇 |
2013年 | 29篇 |
2012年 | 16篇 |
2011年 | 20篇 |
2010年 | 49篇 |
2009年 | 46篇 |
2008年 | 27篇 |
2007年 | 65篇 |
2006年 | 21篇 |
2005年 | 30篇 |
2004年 | 15篇 |
2003年 | 21篇 |
2002年 | 21篇 |
2001年 | 23篇 |
2000年 | 28篇 |
1999年 | 31篇 |
1998年 | 94篇 |
1997年 | 89篇 |
1996年 | 112篇 |
1995年 | 87篇 |
1994年 | 88篇 |
1993年 | 77篇 |
1992年 | 24篇 |
1991年 | 33篇 |
1990年 | 36篇 |
1989年 | 34篇 |
1988年 | 43篇 |
1987年 | 32篇 |
1986年 | 37篇 |
1985年 | 36篇 |
1984年 | 16篇 |
1983年 | 23篇 |
1982年 | 23篇 |
1981年 | 22篇 |
1980年 | 17篇 |
1979年 | 5篇 |
1978年 | 9篇 |
1977年 | 14篇 |
1976年 | 13篇 |
1975年 | 7篇 |
1974年 | 2篇 |
1967年 | 1篇 |
1966年 | 2篇 |
排序方式: 共有1505条查询结果,搜索用时 15 毫秒
91.
Because T-cell responses are critical for defense against viral infections, the synthetic P18 peptide (RIQRGPGRAFVTIGK) and active component of gp160 protein has previously been shown to induce cytotoxic and helper T-lymphocyte responses. In order to further define the T-helper cells, responses which are known to play a role in enhancing the immunological response to foreign antigen, we studied the response of individuals immunized with HIV gp160 candidate vaccines. We investigated the proliferative cellular response of peripheral blood mononuclear cells (PBMC) derived from individuals immunized with gp160 antigens in three different protocols. We found a PBMC proliferative response to synthetic P18 peptide in healthy immunized individuals induced by gp160 antigen with or without vaccinia virus. There was correlation between the proliferative response to P18 peptide and other antigens such as HIV-like proteins and gp160 molecule. HLA-DR typing revealed the possible presentation of P18 peptide by several different class II molecules. Since these class II molecules occur frequently in the general population, P18 peptide appears to contain broadly reactive epitopes and thus is presented by mutiple HLA class II molecules. Due to its broad reactivity P18 peptide is one of the candidates for inclusion as a subunit vaccine against HIV-1. 相似文献
92.
José GM Hofhuis Henk F van Stel Augustinus JP Schrijvers Johannes H Rommes Jan Bakker Peter E Spronk 《Critical care (London, England)》2009,13(1):118-3
During recent years increasing attention has been given to the quality of survival in critical care. Health-related quality
of life (HRQOL) is an important issue both for patients and their families. Furthermore, admission to the intensive care unit
can have adverse psychological effects in critically ill patients. Recent studies conducted in critically ill patients have
measured HRQOL. However, usually absent from such reports are evaluations of conceptual issues, addressing factors such as
why HRQOL should be measured in critically ill patients, how to define and standardize domains of HRQOL, whether proxies can
provide useful information about HRQOL in critically ill patients, whether response shift occurs in critically ill patients,
and whether post-traumatic stress disorder (PTSD) occurs in critically ill patients. Some studies reported moderate agreement
between patients and their proxies, although lower levels of agreement may be reported for psychosocial or physical functioning.
Response shift (adaptation and change in perception) appears to be an important phenomenon and likely to be present, but it
is seldom measured when estimating HRQOL in critically ill patients. Furthermore, vigilance for symptoms of PTSD and early
interventions to prevent PTSD are needed. 相似文献
93.
94.
95.
A Lacout M El Hajjam C Julie P Lacombe JP Pelage 《Journal of Medical Imaging and Radiation Oncology》2008,52(6):580-582
We report the case of a patient with a single liver metastasis of a mucinous colonic carcinoma that mimics a haemangioma in T2‐weighted sequences. Although a very high T2 signal in non‐cystic lesions is highly specific for the diagnostic of haemangioma, the use of gadolinium‐enhancement MRI is recommended. In patients with a history of neoplasia, the diagnosis of benign liver nodules should be made with caution. 相似文献
96.
The frequency of reversible and irreversible visual impairment was determined in children with severe and profound sensorineural deafness, as subnormal vision can adversely affect their educational and social development. Eighty three of 87 such children attending an audiology service were examined to assess the incidence and severity of visual impairment. Each child underwent a detailed ophthalmic assessment. The criteria for visual impairment were visual acuity < 6/9 Snellen or equivalent and/or abnormal binocular vision. Forty five had a normal ophthalmic examination (54.2%). Twenty nine had visual impairment (34.9%) and nine had ophthalmological abnormalities that did not interfere with vision (10.9%). A higher proportion of children with risk factors for visual pathology demonstrated visual impairment than those in whom there were no risk factors. None the less, 44% of visual impairment was among patients without risk factors. The results underline the need to examine all children with severe and profound sensorineural deafness soon after diagnosis and indicate that children with multiple handicaps have a greater likelihood of visual impairment (11 of 14 cases). 相似文献
97.
G Larcos SM Gruenewald JP Fletcher 《Journal of Medical Imaging and Radiation Oncology》1995,39(3):254-256
Recent observations suggest that first degree relatives of patients with an abdominal aortic aneurysm (AAA) are also at risk for the development of this disorder. The first degree relatives of 130 adults with known AAA were invited to attend for an ultrasound examination. Fifty-two eligible relatives (mean age 53 years, range 41–73) from 38 families underwent sonographic screening. Using standard ultrasound criteria no participants were identified with an asymptomatic AAA. Thus, ultrasound of families of patients with AAA has a low yield and may not be useful for screening purposes. 相似文献
98.
99.
Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer 总被引:1,自引:0,他引:1
Neri B Doni L Gemelli MT Fulignati C Turrini M Di Cello V Dominici A Maleci M Mottola A Ponchietti R Raugei A Valsuani G Cini G 《The Journal of urology》2002,168(3):956-958
PURPOSE: Since metastatic renal cell carcinoma has a poor prognosis and treatment strategies, including hormone therapy, chemotherapy and immunotherapy, have little impact on the quality of life and global survival statistics, new interest has recently focused on the combination of immuno-chemotherapy using pyrimidine analogues, such as gemcitabine. MATERIALS AND METHODS: In a phase II study 16 patients with metastatic renal cell carcinoma were treated with 1,000 mg./m. gemcitabine intravenously on days 1, 8, 15 and 28 for 6 months, 3 MU (1 MU = 1 x 10(6) IU) interferon (IFN)-alpha intramuscularly 3 times a week and 4.5 million IU interleukin (IL)-2 subcutaneously daily for 5 days a week for 2 consecutive weeks every month for 6 months. Responding and nonprogressing cases were maintained on immunotherapy consisting of IFN-alpha and IL-2 for further 6 months. RESULTS: In 15 evaluable patients overall response rate (1 complete response plus 3 partial response) was 28% while stable disease was achieved in 7 (47%). Median survival duration was 20 months (range, 9 to 26+) and median time to tumor progression was 14 months (6 to 26+). The complete response lasted 24+ months and partial response lasted 16 months. The regimen was well tolerated with only 1 case of neutropenia (WHO grade 3), while anorexia, fatigue and flu-like symptoms were the most common toxicity problems but were never greater than grade 2. CONCLUSIONS: Despite the small sample size, this study demonstrates that gemcitabine combined with standard doses of IFN-alpha and low doses of IL-2 is effective treatment for metastatic renal cell carcinoma. This biotherapy was well tolerated and resulted in an optimum objective response and relatively long-term survival. 相似文献
100.
Neri B Doni L Fulignati C Gemelli MT Turrini M Di Cello V Dominici A Mottola A Raugei A Ponchietti R Cini G 《Anticancer research》2002,22(5):2981-2984
Combination chemotherapy with newer, more active drugs in patients with advanced and/or metastatic bladder cancer might show improved response rate and survival. Gemcitabine (GEM) and Epidoxorubicin (EPI) have demonstrated activity in this disease. In addition, experimental studies in vitro have shown that the two agents have additive-synergistic effects when used in combination. Our prior phase I dose-finding study in previously untreated patients with advanced or metastatic bladder cancer defined recommended doses for further trials of GEM 1000 mg/m2 and EPI 25 mg/m2 on days 1, 8 and 15 every 28 days. A phase II trial at this dose level was initiated in previously untreated patients to assess efficacy and toxicity. Eligible patients had measurable disease; Karnofsky performance status (PS) of > 40; no prior chemotherapy; and adequate bone marrow reserve, cardiac, hepatic and renal function. Thirty- one patients (22 males, 9 females) with median age of 64 (range 44-75) and median PS of 80 were accrued, and all were eligible. Twelve patients had T4N1-2 M0, 8 had lymph node only metastases, while 11 had visceral metastases (liver, bone, lung). A total of 181 cycles was administered (range 3-7 per patient). Major toxicities (WHO grade > or = 3) were: neutropenia in 5 patients, thrombocytopenia in 2 patients, and anemia in 2 patients. Three patients had febrile neutropenic episodes and only 3 patients required dose reduction. Grade 1-2 non-hematological toxicities included nausea/vomiting, stomatitis and alopecia. No cardiac toxicity was observed. Of the 30 response evaluable patients, 17 (57%) demonstrated a major response (3 complete and 14 partial) (95% CI: 39%-75%), 7 had stable disease (23%) and 6 progressed (20%). These preliminary results confirm the phase I observation that the combination of GEM--EPI is highly active in the treatment of advanced and metastatic bladder cancer with a favourable toxicity profile. 相似文献